Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) – Cognitive sub-study

三联疗法预防复发性脑内疾病事件试验 (TRIDENT) — 认知子研究

• 批准号: nhmrc : GNT1159055
• 金额: $ 141.64万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/triple-therapy-prevention-sub-study/1379064
• 关键词: Triple; therapy; prevention; Recurrent; Intracerebral

Extraordinarily high rates of dementia are evident in survivors of intracerebral haemorrhage (ICH), the most serious form of stroke. This project will determine in 400 subjects from the TRIDENT trial, whether over a 2-year period, the “triple pill’ for intense blood pressure lowering, can reduce memory and cognitive decline in comparison to standard care. A secondary aim will be to examine the key mediators of cognitive decline using brain scanning markers of small vessel disease.

脑出血（脑溢血）是中风最严重的一种形式，脑溢血幸存者中明显存在异常高的痴呆率。该项目将在TRIDENT试验的400名受试者中确定，在2年的时间里，与标准治疗相比，用于剧烈降压的“三联丸”是否能减少记忆和认知能力下降。第二个目标将是使用小血管疾病的脑扫描标记来检查认知能力下降的关键介质。